Whittier Trust Co. of Nevada Inc. Buys 22,578 Shares of Merck & Co., Inc. (NYSE:MRK)

Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 10.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 247,338 shares of the company’s stock after buying an additional 22,578 shares during the quarter. Merck & Co., Inc. comprises 0.9% of Whittier Trust Co. of Nevada Inc.’s investment portfolio, making the stock its 18th largest holding. Whittier Trust Co. of Nevada Inc.’s holdings in Merck & Co., Inc. were worth $32,636,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Cross Staff Investments Inc raised its stake in Merck & Co., Inc. by 3.5% during the fourth quarter. Cross Staff Investments Inc now owns 6,710 shares of the company’s stock worth $732,000 after acquiring an additional 225 shares in the last quarter. PFW Advisors LLC acquired a new position in Merck & Co., Inc. during the first quarter worth $212,000. Dynamic Advisor Solutions LLC raised its stake in Merck & Co., Inc. by 6.0% during the first quarter. Dynamic Advisor Solutions LLC now owns 77,833 shares of the company’s stock worth $10,270,000 after acquiring an additional 4,433 shares in the last quarter. Kennedy Investment Group raised its stake in Merck & Co., Inc. by 16.0% during the fourth quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock worth $280,000 after acquiring an additional 354 shares in the last quarter. Finally, Schear Investment Advisers LLC raised its stake in Merck & Co., Inc. by 16.0% during the fourth quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock worth $352,000 after acquiring an additional 445 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $126.74 on Wednesday. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $134.63. The stock has a market cap of $321.01 billion, a P/E ratio of 140.09, a price-to-earnings-growth ratio of 2.43 and a beta of 0.38. The stock’s 50-day moving average price is $128.99 and its two-hundred day moving average price is $125.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. During the same quarter last year, the business earned $1.40 earnings per share. The company’s revenue was up 8.9% compared to the same quarter last year. On average, equities analysts predict that Merck & Co., Inc. will post 8.62 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, July 8th. Shareholders of record on Monday, June 17th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.43%. The ex-dividend date of this dividend was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 342.22%.

Analysts Set New Price Targets

MRK has been the subject of several recent analyst reports. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. Wells Fargo & Company increased their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. Berenberg Bank increased their target price on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Finally, Truist Financial increased their target price on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average target price of $133.00.

Check Out Our Latest Research Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.